MARKET

CASI

CASI

Casi Pharmaceuticals Inc
NASDAQ
1.950
-0.020
-1.02%
After Hours: 1.980 +0.03 +1.54% 16:00 12/02 EST
OPEN
2.000
PREV CLOSE
1.970
HIGH
2.050
LOW
1.950
VOLUME
70.83K
TURNOVER
0
52 WEEK HIGH
10.30
52 WEEK LOW
1.810
MARKET CAP
26.53M
P/E (TTM)
-0.9897
1D
5D
1M
3M
1Y
5Y
CASI Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations
CASI Pharmaceuticals ( NASDAQ:CASI ) Third Quarter 2022 Results Key Financial Results Revenue: US$10.2m (up 26% from 3Q...
Simply Wall St. · 11/17 10:39
BTIG Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10
Benzinga · 11/16 13:26
--BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating
--BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating
MT Newswires · 11/16 09:39
HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10
Benzinga · 11/15 11:13
CASI Pharmaceuticals GAAP EPS of -$0.38 beats by $0.08, revenue of $10.21M beats by $0.3M
Seekingalpha · 11/14 14:11
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/14 13:15
BRIEF-Casi Pharmaceuticals Announces Third Quarter 2022 Financial Results
Reuters · 11/14 12:58
CASI Pharmaceuticals Q3 EPS $(0.38) Up From $(0.73) YoY, Sales $10.21M Up From $8.11M YoY
Benzinga · 11/14 12:35
More
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. It is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.